{"name":"Thryv Therapeutics, Inc.","slug":"thryv-therapeutics-inc","ticker":"","exchange":"","domain":"thryv.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiywJBVV95cUxPMjNBSURzX0N3SVpZeXhKLWVNRWxMaWNtaS1PN2RuY19lRms2VXpFM0JtSnBzZGtrNUpybHVmOURBZkpqY09qdDNGMlJDd2l1SFhmSE9QYUczWGZiZnkxdUU0VElDUkhMNnhQMW9EOUpyTjR5ejFTd2lSWW02RmlicENvV2owRUpyY2ZNXzQ3QVQtQ21lWkxDaXUyMWFpNDlqZzBYV194N2VPTmhzX3hacW5LZ1hxOXk0Wk5pNkNQYTVEQUJXcTZxQlBPaG5ZYlNqUmR5bzhHSTRjZlhoOGpaWUpSU1J3aURxRmJmVy1MdnhUa3A3ajNuRnVMamcxS3R1VDNPMkRsa0s3S1phcUFzeUY2LVVkcG9QNy10cEE2VzJCdkZhTmQ2S0FMVnUxc3hDMC1jblRkN0xMdVBfaThwN28xQk1FbzhOdDFv?oc=5","date":"2026-03-26","type":"trial","source":"Barchart.com","summary":"Atrial Fibrillation Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Bayer, Johnson and Johnson, Bristol Myers-Squibb, Daiichi Sankyo, Pfizer, Anthos Therap - B","headline":"Atrial Fibrillation Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Bayer, John","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOT1JvTlVzQ2Q0OUpoNEswcXRlWVpQSkdHTWo3U0Vna2lzb29oRlFwQnhYaGx0Wk5wa0tHQ1o0dUtpbUQxOFpZT0hXQ2VRVU5MVWVLNVZnQ2ZmRHhtZS1rZnkwR0paNkRrdnBlOFJzeHQzU2J0d0sxVkVHMlFuSGNhblFSU2pMeXpGUkxCNkFaMEl5Zw?oc=5","date":"2025-12-05","type":"pipeline","source":"Fierce Biotech","summary":"Yet another CDER leadership shake-up—Chutes & Ladders - Fierce Biotech","headline":"Yet another CDER leadership shake-up—Chutes & Ladders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPYmNVUEp3bnpvYXItWDFneERBS2VDeXd2TU5Cc3h4M05lcGlDNFFfd2NnQzc2SFF3a2thODc1OTFkR3pBMkN6SDRWRFMtWG02aGRFWFQ2YXN0RTNFWVFaMkIzd3I4V2x0SXVRMG42Sy1GcG5OSXVDOGx3TE9vYThqaTlBa3VnMUp0VmlXeVlDR1JyYzBm?oc=5","date":"2025-09-30","type":"trial","source":"Yahoo Finance","summary":"Atrial Fibrillation Clinical Trials & Pipeline Overview: Insights into 12+ Leading Companies and 15+ Novel Treatments | DelveInsight - Yahoo Finance","headline":"Atrial Fibrillation Clinical Trials & Pipeline Overview: Insights into 12+ Leading Companies and 15+ Novel Treatments | ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQbUNjUnY0NmE4ellteUtEWGxPMHl2SWF3Q1RrYnVDYjBSWFJsaDIzQjE0VVpsYy1DUUlDVjRzQjlHbUYwMDU1ZWFXVTFiWWhaeUYzMnpIc2hxSkZraGs5UnNVMUk0eEx5aTVmNVNWSlhhRlBsV0NtclpsdzgtTVFRcVdwS2JzQlo1TmZ0NktxVll6N2VtQmg4SWdlamJOZy1pSWxiT0dfNEdVNGcyT21LSm1NTl9meE1BZk4tWg?oc=5","date":"2025-09-18","type":"regulatory","source":"BioSpace","summary":"Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome - BioSpace","headline":"Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFAta0U2N3FIN0k4em5rcHdpNGdaS3BjSWRVVHZqTWt5ZExDTEFRWUlXbS1Cd29CbFRHMVlqS2xSaWttWjdiT19idlB1elRMYWxJMVhfRl9kT0I1dEVJU3NmcjNaY3VKVHhDczFmeWFYSE1Ianh2bnJuSVdXRQ?oc=5","date":"2025-01-23","type":"trial","source":"Wiley","summary":"A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers - Wiley","headline":"A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination w","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQNTR5WDR2UmZneVZCWFpjUUExeHRhN2ZyM2wyOS1xVk1iUm9vbm5sZkpYSGJfaW1XMzBvZHlNcTV3cGdTbVpEOHpDWG4zcEc2dmNyT3BKRkhrWmw1MHpsQVZiWElPQWdVbE0yX1pqTkFVX2NDWFJzVklrUnlITUlwa2pxQi1YY3NWbFRKMEEtTUdJUV9IbXp4bU9n?oc=5","date":"2024-11-22","type":"pipeline","source":"Fierce Biotech","summary":"Pfizer replaces retiring CSO with cancer chief—Chutes & Ladders - Fierce Biotech","headline":"Pfizer replaces retiring CSO with cancer chief—Chutes & Ladders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQZUNvU0c0N0tpWnNidFFSZ0YyYjhfdnpQMHNIWUx3NFdpSFdHZkhDX25ZNXpRcDhLY3BLY1AzQUhtRzV1bllMdkV6QWhMQ0pMRHlIUXJhQkFZYk9PUE5rVGVsdjJEWWFuMV9fdHhEb3lVZFBpWTY5bzRaQUFRZzc0QTFjT0g3SW1ULVh3SEptSnFFM2RnbU9fMFBybmQxbklaU3ZVSEhWaExkeE9rdVNrUHl4bXJfcUhXU1lqSVhn?oc=5","date":"2024-10-04","type":"regulatory","source":"pharmacytimes.com","summary":"FDA Grants Orphan Drug Designation to LQT-1213 to Treat Patients With Long QT Syndrome - pharmacytimes.com","headline":"FDA Grants Orphan Drug Designation to LQT-1213 to Treat Patients With Long QT Syndrome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOa2FuaTJCR1d0NkVQbmkyUHIta0IxbHphZDZkMU1VVHZXMDdhU005dHNqYVVyRmZUNjRPS19LUWYzXzZmZGlDcDQyOWhhZ0o1Mm13OU52Mk1IcWctYmliSUhrZ1FvUDdZVlQ3Z0RiVG96UUpENjVDakV4dVpJcTZrbnpsdENRZkhyNENYVXcydWJtSnJlRTNLamhBcWhfT1ppZldHelB3?oc=5","date":"2024-07-03","type":"pipeline","source":"World Business Outlook","summary":"Acurex Biosciences welcomes Dr. Robert Booth to its Board of Directors - World Business Outlook","headline":"Acurex Biosciences welcomes Dr. Robert Booth to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNS0xJRzdqU1hkaEV3c1BzZHd3V1BvUjFoLWo3aW80SktGMWdNaFBJYkViTE9YbkNxcy03WjNTTU1XbTlVMkdHWWdmeXJobFZIcnVVZ1BlcVJPX2VWenhyV2J4dFdodTBWcDZOTklYNDBvMXpURnZMQnhLa2d5WmcwWkRoTU53Nnd4aGFsY1c2MTU0SmZrUDhQeU14VkRMeXRNdW5nVU9Xal9Sd1JFZGRlMU5CMzNNTGlZSGJuUzhvWQ?oc=5","date":"2024-05-10","type":"trial","source":"The ASCO Post","summary":"Selective Targeting of PARP1 in Early-Phase Study Shows Activity in Breast Cancer - The ASCO Post","headline":"Selective Targeting of PARP1 in Early-Phase Study Shows Activity in Breast Cancer","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}